EUVIMEDEUVIMED entdecken
Crossref

Interview for Breast Cancer Management with Dr David Montgomery: Marketing Authorization for Pfizer’s Metastatic Breast Cancer Treatment, Palbociclib (Ibrance®) in Combination with Endocrine Therapy

David Montgomery

Breast Cancer Management · 2016

DOI: 10.2217/bmt-2017-0006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Management, 2016. Verfasst von David Montgomery. Die Arbeit nennt 25 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Montgomery, D. (2016). Interview for Breast Cancer Management with Dr David Montgomery: Marketing Authorization for Pfizer’s Metastatic Breast Cancer Treatment, Palbociclib (Ibrance®) in Combination with Endocrine Therapy. Breast Cancer Management. https://doi.org/10.2217/bmt-2017-0006

Vancouver

Montgomery D. Interview for Breast Cancer Management with Dr David Montgomery: Marketing Authorization for Pfizer’s Metastatic Breast Cancer Treatment, Palbociclib (Ibrance®) in Combination with Endocrine Therapy. Breast Cancer Management. 2016. doi:10.2217/bmt-2017-0006

BibTeX
@article{Montgomery2016,
  author = {Montgomery, David},
  title = {Interview for Breast Cancer Management with Dr David Montgomery: Marketing Authorization for Pfizer’s Metastatic Breast Cancer Treatment, Palbociclib (Ibrance®) in Combination with Endocrine Therapy},
  journal = {Breast Cancer Management},
  year = {2016},
  doi = {10.2217/bmt-2017-0006}
}
Kostenlos starten →